Saint Luke’s Cancer Institute

The team at Saint Luke’s Cancer Institute provides early detection, expert diagnosis, personalized treatment options, and survivorship support to every patient. It’s what Saint Luke’s calls precision medicine: the right treatment for the right patient at the right time.

We offer the region’s only precision oncology program for advanced cancers that is staffed by clinical oncologists with expertise in genomic sequencing and computational biology. With our clinical trial agreement with the internationally recognized Washington University School of Medicine, we can offer more than 200 National Cancer Institute-sponsored clinical trials and industry-led studies to patients receiving care at Saint Luke's Cancer Institute. 

Personalized Cancer Treatment

Saint Luke’s Cancer Institute offers options for patients at every stage in their cancer journey:

• Medical oncologists and hematologists who subspecialize in every type of cancer, including breast, lung, gastrointestinal, liver, brain, gynecologic, and colon
• Genomic sequencing and precision oncology services for advanced cancers
• A Multidisciplinary Breast Clinic where patients meet with a team of specialists in one comprehensive appointment
• The region’s largest network of 3D mammography centers for early detection of the smallest tumors
• Nurse navigators who serve as patient resources and advocate through treatment and beyond
• Innovative surgeries for brain tumors
• Supportive Oncology and Rehabilitative Services program to help patients overcome the physical and emotional challenges that often follow diagnosis and treatment
• Radiation Oncology offering leading-edge technology at four convenient metro locations

Second Opinions

When it comes to potentially life-changing or life-saving treatments, patients and their families often seek a second opinion. Second opinions can provide:

• Confirmation of a diagnosis
• More details about type of cancer and stage, which affect treatment options
• Perspective from subspecialized oncologists

If you started your cancer journey at another facility, the experts at Saint Luke’s Cancer Institute are available to review your records and provide a thoughtful second opinion, including personalized treatment options available at Saint Luke’s.

Classes and Events

• Gilda’s Club Kansas City
• Look Good Feel Better
• Breast Cancer Support Groups
• Nutrition for Cancer Survivorship 
• Dr. Jeffrey Wieman Cancer Prevention Lecture Series 

View all classes and events.

Clinical Trials Available at Saint Luke's

For more information about clinical trials at Saint Luke's Cancer Institute, call 816-932-2677.

Advanced Solid Tumor

• SGNDV-004: A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors
• STX-478-101: First-in-Human Study of STX-478, a H1047X Mutation-specific PI3K? Inhibitor as Monotherapy and in Combination with Other Antineoplastic Agents in Advanced Solid Tumor Patients 
• Tempus REC-4881-221: A Phase 2, Open-Label Study of REC-4881 in Participants With Unresectable Locally Advanced or Metastatic Cancer With AXIN1 or APC Mutation
• XL309-101: An Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of XL309 (ISM3091) as Single-Agent and Combination Therapy in Patients with Advanced Solid Tumors

Brain Cancer

• NRG-BN012: A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
• NVX-108-GBM-P2: A Phase 2 Study of NanO2(TM) Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM (RESTORE)
• Pro00113395: A multicenter trial to identify optimal atezolizumab biomarkers in the setting of recurrent gliobastoma. The (MOAB) Trial

Breast Cancer

• A01180: CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinb
• A012103: OptimICE-pCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
• C4391002: A phase 1B/2, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of PF-07220060 in combination with PF-07104091 plus endocrine therapy in participants with advanced solid tumors.
• C4891001: A phase 3, randomized, open-label, multicenter trial of ARV-471 (PF-07850327) vs. fulvestrant in participants with estrogen receptor-positive, HER2-negative advanced breast cancer whose disease progressed after prior endocrine based treatment for advanced disease.
• CBYL719AoUS03T: Alpelisib, fulvestrant and dapagliflozin for the treatment of HR+, HER2 -, PIK3CA mutant metastatic breast cancer
• CT7001_002 SUMIT-BC: An Open-Label interventional, multi-center, randomized, Phase 2 Study of Fulvestrant with or without Samuraciclib in Participants with Metastatic or Locally Advanced Hormone Receptor Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
• D8535C00001: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
• D926XC00001: A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
• DB-1303-O-3002: A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy
• GS-US-598-6168: Phase 3 Breast Cancer Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice
• SGNTUC-028: A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer
• SMX22-002: Phase 3 open label study comparing efficacy and safety of the combination of lasofoxifene and abemaciclib to the combination of fulvestrant and abemaciclib for the treatment of adults with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation 

Colorectal Cancer

• NRG-Gi008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
• CRDF-004: A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation

Hepatocellular Carcinoma (HCC) 

• ML44719-A: A Phase II, Open-Label, Multicohort, Multicenter Study in Patients with Hepatocellular Carcinoma and Child-Pugh B Cirrhosis.

Lung Cancer

• 202108023: Palbociclib and Cetuximab versus Cetuximab Monotherapy for Patients with CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma who Experienced Disease Progression on a PD-1/L1 Inhibitor: A Multicenter, Open-Label, Randomized Phase 3 Trial
• A081801: Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
• A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
• D419ML00003: A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)
• HLX10-005-SCLC301-E: A Randomized, Open-label Study of HLX10 plus Chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
• M18-868: A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
• S2302: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
• SGNB6A-002: A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer
• LUNG MAP: Master Protocol for Treatment of Non-Small Cell Lung Cancer
• S1900E: A phase II study of sotorasib (AMG 510) in participants with previously treated stage IV or recurrent KRAS G12C mutated non-squamous non-small cell lung cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
• S1900K: A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung- MAP Sub-Study)

Pancreatic Cancer

• EA2192 APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Supportive Care

• TTX-CINP-202: A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain